| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CMDC.200600221 |
| P8608 | Fatcat ID | release_34jbtmchlnelzoamvjvyeatn5m |
| P698 | PubMed publication ID | 17154430 |
| P5875 | ResearchGate publication ID | 6645799 |
| P2093 | author name string | Peter R Young | |
| Jill M Spoerke | |||
| Zhengying Pan | |||
| Paul A Sprengeler | |||
| Heleen Scheerens | |||
| James T Palmer | |||
| Brian E Schultz | |||
| Douglas A Jeffery | |||
| Lee A Honigberg | |||
| Rohan V Mendonca | |||
| Keana C K Scott | |||
| Stacie A Dalrymple | |||
| L Chuck Burrill | |||
| Michael D Sweeney | |||
| Paul G Grothaus | |||
| Shyr-Jiann Li | |||
| P2860 | cites work | Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors | Q27619043 |
| Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia | Q27634627 | ||
| Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor | Q28368986 | ||
| Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide] | Q28372191 | ||
| Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA) | Q28569704 | ||
| A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 | ||
| 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity | Q30658242 | ||
| Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes | Q31017238 | ||
| Tec kinases: modulators of lymphocyte signaling and development | Q34282327 | ||
| Irreversible inhibitors of the erbB family of protein tyrosine kinases | Q34792935 | ||
| Therapeutic strategies for rheumatoid arthritis | Q35140855 | ||
| Features of selective kinase inhibitors | Q36173396 | ||
| Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement | Q36368492 | ||
| Structural bioinformatics-based design of selective, irreversible kinase inhibitors | Q40307105 | ||
| Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. | Q40457478 | ||
| Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor | Q40951781 | ||
| Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I | Q73022511 | ||
| Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era | Q77796116 | ||
| Structural basis for selective inhibition of Src family kinases by PP1 | Q78192599 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 58-61 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | |
| P478 | volume | 2 |
| Q90284350 | A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification |
| Q91799952 | A comprehensive review of protein kinase inhibitors for cancer therapy |
| Q43122434 | A computational workflow for the design of irreversible inhibitors of protein kinases. |
| Q35794593 | A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia |
| Q38944958 | A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells |
| Q40840109 | A multitude of kinases--which are the best targets in treating rheumatoid arthritis? |
| Q36288294 | A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase |
| Q36517276 | A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies |
| Q91735722 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia |
| Q34067085 | A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors |
| Q34061522 | A structure-guided approach to creating covalent FGFR inhibitors |
| Q38114501 | Aberrant B cell selection and activation in systemic lupus erythematosus |
| Q40454778 | An enriched structural kinase database to enable kinome-wide structure-based analyses and drug discovery |
| Q36548443 | Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function |
| Q39339730 | Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 |
| Q38989374 | Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview |
| Q47153340 | Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors |
| Q90289399 | Association between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takostubo's cardiomyopathy |
| Q47921236 | Automated computational screening of the thiol reactivity of substituted alkenes. |
| Q38124119 | B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities |
| Q38185363 | B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies |
| Q34398579 | B-cell receptor signaling as a driver of lymphoma development and evolution |
| Q26765624 | BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia |
| Q38101590 | BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies |
| Q38581000 | BTK Signaling in B Cell Differentiation and Autoimmunity |
| Q47164914 | BTK blocks the inhibitory effects of MDM2 on p53 activity |
| Q34041311 | BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future |
| Q58751656 | BTK modulates p73 activity to induce apoptosis independently of p53 |
| Q58594085 | BTK: a two-faced effector in cancer and tumour suppression |
| Q38205852 | Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. |
| Q37997075 | Bruton tyrosine kinase (BTK) and its role in B-cell malignancy |
| Q38989496 | Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside |
| Q38083077 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). |
| Q35181271 | Bruton's TK inhibitors: structural insights and evolution of clinical candidates |
| Q96132815 | Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer |
| Q38766891 | Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. |
| Q46217363 | Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. |
| Q34039406 | Bruton's tyrosine kinase (BTK) inhibitors in clinical trials |
| Q37787243 | Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity |
| Q38351380 | Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas |
| Q38834459 | Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. |
| Q45752089 | Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells |
| Q41524241 | Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies |
| Q42329453 | Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma |
| Q94569352 | Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms |
| Q27309998 | CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors |
| Q50065065 | Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways |
| Q37427124 | Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses |
| Q28271836 | Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses |
| Q51072600 | Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. |
| Q36654176 | Chemical Methods for Encoding and Decoding of Posttranslational Modifications |
| Q93044159 | Chemoproteomics of an Indole-Based Quinone Epoxide Identifies Druggable Vulnerabilities in Vancomycin-Resistant Staphylococcus aureus |
| Q26764833 | Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents |
| Q24613755 | Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma |
| Q38675358 | Chronic lymphocytic leukemia (CLL)-Then and now. |
| Q43218078 | Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase |
| Q27704055 | Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity |
| Q29248430 | Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions |
| Q36072400 | Covalent Tethering of Fragments For Covalent Probe Discovery |
| Q92347508 | Cross-talk between Myc and p53 in B-cell lymphomas |
| Q39325783 | Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies |
| Q90170696 | Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines |
| Q24672143 | Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach |
| Q34324177 | Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor. |
| Q33859476 | Determining Cysteines Available for Covalent Inhibition Across the Human Kinome |
| Q38582791 | Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies |
| Q38714409 | Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment |
| Q54279430 | Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. |
| Q48016248 | Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold. |
| Q27679513 | Discovery of Novel Irreversible Inhibitors of Interleukin (IL)-2-inducible Tyrosine Kinase (Itk) by Targeting Cysteine 442 in the ATP Pocket |
| Q46244831 | Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ. |
| Q37180382 | Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia |
| Q42581497 | Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma |
| Q30009417 | Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors. |
| Q64930674 | Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation. |
| Q36462375 | Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia |
| Q34280885 | Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) |
| Q33437322 | First-line therapy for young patients with CLL. |
| Q38817591 | From identification of the BTK kinase to effective management of leukemia. |
| Q33841419 | Future therapeutic targets in rheumatoid arthritis? |
| Q46910368 | Global profiling of lysine reactivity and ligandability in the human proteome. |
| Q64274976 | Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas |
| Q90241391 | Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement |
| Q59798766 | Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites |
| Q58782275 | How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD |
| Q53704804 | ITK inhibition for the targeted treatment of CTCL. |
| Q26852328 | Ibrutinib (PCI-32765) in chronic lymphocytic leukemia |
| Q50050288 | Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. |
| Q38130010 | Ibrutinib and novel BTK inhibitors in clinical development |
| Q37555418 | Ibrutinib for B cell malignancies |
| Q38694168 | Ibrutinib for mantle cell lymphoma |
| Q38765015 | Ibrutinib for treatment of chronic lymphocytic leukemia |
| Q90103630 | Ibrutinib in primary central nervous system diffuse large B-cell lymphoma |
| Q33714712 | Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL |
| Q36544565 | Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells |
| Q38857067 | Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. |
| Q37688439 | Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation |
| Q38650087 | Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia |
| Q38585329 | Ibrutinib-A double-edge sword in cancer and autoimmune disorders. |
| Q34289493 | Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. |
| Q38557067 | Ibrutinib: from bench side to clinical implications. |
| Q38996766 | Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival |
| Q41852151 | Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor |
| Q34722000 | Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. |
| Q38989227 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1. |
| Q101121282 | Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances |
| Q36219647 | Initial treatment of CLL: integrating biology and functional status |
| Q36020943 | Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma |
| Q34307423 | Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions |
| Q57230716 | MS methods to study macromolecule-ligand interaction: Applications in drug discovery |
| Q37723475 | MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. |
| Q38413580 | Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma |
| Q35581292 | Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma |
| Q52578340 | Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR. |
| Q39147488 | Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy |
| Q42933562 | More than just B-cell inhibition |
| Q38860970 | Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition |
| Q58088981 | Neolymphostin A is a Covalent Phosphoinositide-3-kinase (PI3-K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor that Employs an Unusual Electrophilic Vinylogous Ester |
| Q36404778 | Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL |
| Q36673755 | Novel Bruton's tyrosine kinase inhibitors currently in development |
| Q52645038 | Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q35558057 | Novel and emerging targeted-based cancer therapy agents and methods |
| Q43185847 | Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. |
| Q33849388 | Oncogenic activation of NF-kappaB. |
| Q37980900 | PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies |
| Q89014299 | PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies |
| Q92310282 | PROTACs: great opportunities for academia and industry |
| Q38544216 | Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q46648296 | Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition |
| Q39433250 | Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors |
| Q91796904 | Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening |
| Q31097476 | Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group |
| Q37552578 | Regulation of B cell fate by chronic activity of the IgE B cell receptor |
| Q53691981 | Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. |
| Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
| Q52919884 | Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. |
| Q90557108 | Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants |
| Q34354339 | Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells |
| Q36240848 | Signal transduction and chemotaxis in mast cells |
| Q89866309 | Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia |
| Q38938436 | Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor |
| Q42116442 | Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs |
| Q102075600 | Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes |
| Q37742056 | Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia |
| Q91142553 | Sterile particle-induced inflammation is mediated by macrophages releasing IL-33 through a Bruton's tyrosine kinase-dependent pathway |
| Q57811528 | Stimulus strength determines the BTK-dependence of the SHIP1-deficient phenotype in IgE/antigen-triggered mast cells |
| Q64095477 | Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane |
| Q27658863 | Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases |
| Q38765458 | Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. |
| Q47911423 | Synthesis of 3-(1,2,3-triazol-1-yl)- and 3-(1,2,3-triazol-4-yl)-substituted pyrazolo[3,4-d]pyrimidin-4-amines via click chemistry: potential inhibitors of the Plasmodium falciparum PfPK7 protein kinase |
| Q36208936 | TSLP signaling network revealed by SILAC-based phosphoproteomics |
| Q38975656 | Targeting B cells in treatment of autoimmunity |
| Q58613953 | Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies |
| Q38351184 | Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies |
| Q37468293 | Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases. |
| Q30390894 | Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery |
| Q29547395 | Targeting cancer with small molecule kinase inhibitors |
| Q35172875 | Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. |
| Q38554422 | Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances |
| Q38085501 | Targeting pathological B cell receptor signalling in lymphoid malignancies |
| Q38268506 | Targeting protein kinases with selective and semipromiscuous covalent inhibitors |
| Q38012179 | Targeting the B cell receptor pathway in chronic lymphocytic leukemia |
| Q90044840 | Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors |
| Q28087772 | Targets for Ibrutinib Beyond B Cell Malignancies |
| Q37997073 | Tec family kinases in inflammation and disease |
| Q26849417 | Ten things you should know about protein kinases: IUPHAR Review 14 |
| Q64234280 | The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K |
| Q24633214 | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy |
| Q34029869 | The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo |
| Q35583403 | The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. |
| Q40971353 | The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages |
| Q39180275 | The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia |
| Q91620295 | The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani |
| Q57752422 | The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases |
| Q56675654 | The Taxonomy of Covalent Inhibitors |
| Q42682371 | The role of B cell antigen receptors in mantle cell lymphoma. |
| Q38728631 | The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy |
| Q37570334 | The roles of counterion and water in a stereoselective cysteine-catalyzed Rauhut-Currier reaction: a challenge for computational chemistry |
| Q39091822 | Treatment approaches of hard-to-treat non-Hodgkin lymphomas |
| Q89651597 | Turning liabilities into opportunities: Off-target based drug repurposing in cancer |
| Q38011765 | Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders |
| Q37506087 | Tyrosine kinases as targets for the treatment of rheumatoid arthritis |
| Q27672770 | X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase |
| Q89454901 | [Clinical study and application of Ibrutinib in B-cell non-Hodgkin's lymphomas] |
Search more.